HomeNewsOncology

  • Venclexta/Venclyxto improved overall survival in previously untreated AML patients

    • March 26, 2020
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Post-HSCT Cyclophosphamide use Improves Transplantation Outcomes for AML/MDS

    • March 22, 2020
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • FDA approves Opdivo® + Yervoy® for HCC patients previously treated with sorafenib

    • March 22, 2020
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more

  • Shire Announces Sale of Oncology Business to Servier for $2.4 Billion to Focus on Rare Disease Leadership

    • April 18, 2018
    • Posted by: PharmaScroll
    • Category:
    No Comments
    read more
SPEAK TO AN EXPERT